Letter to Shareholders: From the Desk of Curt Fairbrother CEO

CORONA, CA--(Marketwired - November 02, 2015) - Acology Inc. (OTC PINK: ACOL)

Dear Acology Shareholders:

Since my last letter to you on October 7 there have been several positive developments that I want to share with you.

One year ago, in October 2014, Acology had contracted and sold its products to less than 45 North American distributors. By the end of 2015 Acology will have acquired, contracted and sold products to more than 900 domestic and international distributors, wholesalers, merchants and brokers. This impressive achievement has succeeded in increasing sales for each calendar month of 2015. These results, along with the continuing execution of both new and ongoing marketing efforts, promise steady growth for calendar 2016. Reorders have continued to advance due to very aggressive sales and marketing and a strong social media campaign. October will set another record for the largest gross-sales receipts in the company's history.

Acology is advancing on the medical-device front as well. After welcoming Dr. Vincent Nguyen, DO.,CMD and Program Director of Hoag Hospital's CARES Palliative Care Program and colleges Josh Luke, PHD, Director of the National Re-Admission Coalition Cooperative and Michael Demoratz, PHD, Administrator of 24/7 Care to Acology's Advisory Board, we gathered in formal session on the 27^th of October for the purpose of beginning the collaboration needed to make a strong entrance into the hospice, palliative and cognitive care industries with our signature product, The MedTainer™. Affording Acology executives their rare insight and expertise in these fields these three distinguished men have begun guiding Acology to contacts in the medical device and patient care industry, including large corporate entities centered in Southern California. The MedTainer is now in clinical trials with several large, nation-wide patient care providers who have been supplied with Acology's patented product and are using MedTainers to improve their patient's medication control. In the short time that the trials have run the feedback from clinicians and care givers has been very positive. Acology's intention is to fully capitalize these successful clinical outcomes and create substantial MedTainer sales in these markets.

Responding to the need to increase the capabilities and capacity of our business operations Acology's expansion and building of the new 5,000 sq.ft. extension continues and the intention is to be fully operational by the close of 2015.

Thank you for your continued support.

Sincerely,

Curt Fairbrother, CEO

Acology Inc. / D&C Distributors, LLC

Safe Harbor Statement

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

Acology Inc. and D&C Distributors are located in their production and distribution facility at 1620 Commerce St. Corona, California, 92880. Acology trades on the OTC under the call letters ACOL. The company's email is www.Acologyinc.com. Please send inquiries to info@acologyinc.com or call (844) ACOLOGY (844-226-5649).